Carma Laboratories Launches New Carmex(R) Web Site; Unveils Top 10 Reasons for a Vir...( MILWAUKEE Nov. 19 /- Carma Laboratori...),Health
Navigation Links
Carma Laboratories Launches New Carmex(R) Web Site; Unveils Top 10 Reasons for a Virtual Visit
Date:11/19/2008
MILWAUKEE, Nov. 19 /PRNewswire/ -- Carma Laboratories, Inc., the makers of Carmex(R) lip balms, today unveiled its new Web site: http://www.mycarmex.com. In association with the new site's launch, the company also announced the top 10 reasons to visit mycarmex.com.
"We know that Carmex users are serious about their lip balm and they also have a passion for enjoying life," said Paul Woelbing, president of Carma Laboratories. "The new Web site reflects this lifestyle and enables our customers to insert Carmex fun into more than just their pocket or purse," he added.
Woelbing went on to say, "For years we have had to ward off rumors that our lip balm is addictive, even though all Carmex products are in full compliance with the Food and Drug Administration. However, I cannot make that claim about mycarmex.com -- the new Web site may be habit forming," he added.
In addition to fun, interactive activities that allow visitors to create their own electronic greetings or design their own branded apparel, mycarmex.com features more traditional offerings, such as product descriptions, company history and answers to commonly (and not so commonly) asked questions.
Carmex lip balm is available in a variety of forms like jar, tube and stick; a variety of flavors like cherry, strawberry and mint; and many with sun protection.
Top 10 Reasons to Visit mycarmex.com
10) Launch your movie career (direct link to YouTube to upload Carmex
videos).
9) Find out what supermodels and the TSA have in common.
8) Get free stuff (50 lucky winners chosen each week)!
7) Plan a Carmex fashion show, complete with branded shirts, shoes and
skateboards.
6) Get into the holiday spirit (a portion of proceeds from merchandise
sales will support Toys for Tots).
5) Discover double-secre
'/>"/>
| SOURCE Carma Laboratories, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
(Date:12/4/2009)... Dec. 4 The following i...inz Family Philanthropies: ,, Credit Senators J...gnificant contribution to the health care debate: ...ns living with Phenylketonuria (PKU) control their...rs living with serious chronic conditions are trea...
(Date:12/4/2009)... ischemic stroke are at higher lifetime risk for a... reduce that risk. One of the simplest regimens in... as blood thinners, of which the most common is as...whether the use of antithrombotic medications amon...iod found that in each of the years, approximately...
(Date:12/4/2009)... Tender Corp., a leading manufacturer of over-the...gned to enhance consumers’ quality of life, ...ed American Podiatric Medical Association (APMA) S..., HealthiFeet®. , (P...manufacturer of over-the-counter topical cream and...
(Date:12/4/2009)...Ind., Dec. 4 Hill-Rom Ho...scal 2010 first quarter dividend of $0.1025 per sh...d of Directors on December 3, 2009, and is payable...s of December 17, 2009. ,, ABOUT HILL-ROM ...wide manufacturer and provider of medical technolo...
(Date:12/4/2009)...nn., Dec. 4 MedClean Tec...nnounced the Company has entered into a preferred ..., LLC, a Delaware limited liability company, doin...LLC. Pursuant to the Purchase Agreement, MedClean ... The Company agreed to sell up to 750 shares of it...
Breaking Medicine News(10 mins):Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 2Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 3Health News:Are stroke survivors taking their medicine? 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 3Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 4Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3[0] Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move[0] Are stroke survivors taking their medicine?[0] Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval[0] Hill-Rom Announces First Quarter 2010 Dividend[0] MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million
...y College London and Imperial College London have ...sy environment, such as a pub or in a crowd. // Th...ain work together to make sense of what it hears, ...perience of people who rely on cochlear implants, ...
...tting ready to go home.
Savage, who received ...mber last, says he feels sensation in his// new li...and in a ghastly machine press accident.
Savag...ansplant surgeries.
Savage, who reported sensa...
...r educated about the risks of exposing children to...h researchers.//
Results from a 14-year stu...e more likely to suffer respiratory problems.
...rn Australia say the evidence supports a ban on sm...
...ommended a maximum residue limit (MRL) of one part... the panel has suggested that the limit should be ...nsumer safety.
The panel is headed by the ch...f a controversy over pesticide residues in colas. ...
... issue in quality of life for patients with chroni...peaker, advocate and rheumatology patient, is// ou...nals address this aspect of care. During an hour-l... experiences. Perhaps most importantly, she’ll be ...
...rs seem to have tapped nature, in the form of an e...a possible cure for a notorious type of childhood/...a accounts for nearly 3% of all cancers in childre...'Brien of the University of California, San Franci...
Other Medicine News:Health News:Making Sense of the World Through a Cochlear Implant 2Health News:Destroying Taboos to Improve Patient Care 2(Date:12/3/2009)...c. 3 Radiology imaging leader MEDR...ration capabilities at the November 2009 Radiology...t.PACS(TM) product, enabling the first radiology ...t release in the company,s newly branded Certegra...://www.newscom.com/cgi-bin/prnh/20091203/NE20631 ...
(Date:12/3/2009).... 3 Wound Management...rapidly growing provider of specialty medical prod... Industry Representative Association (HIRA) to ser...ing representative to market the company,s core Ce...IRA will market and sell Wound Management Technolo...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 1Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 2Sigma Aldrich Acquires ChemNavigator Inc to Provide Researchers With Industry Leading Chemical Compound Selection and Procurement Services 13431 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 1SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 13427 10Combo Treatment May Ease Depression After Stroke 53891 1Combo Treatment May Ease Depression After Stroke 53891 2[0] MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009[0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up[0] Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
...ONTO, Feb. 15 A seven-year, international,study p...es such as,acupuncture, neck manipulation and mass...ck pain than many current practices. Also included...exercises, education, neck,mobilization, low level...h as neck collars and ultrasound are not recommend...
...TH SAN FRANCISCO, Calif., Feb. 15 Cell,Genesys, I...an analysis,examining the potential association be...rostate cancer and increased patient survival in a...e refractory prostate cancer,(HRPC). More than 400...were,identified in the sera of the treated patient...
Other Medicine Technology:Seven-Year Neck Pain Study Sheds Light on Best Care 2Seven-Year Neck Pain Study Sheds Light on Best Care 3Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 3Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 4Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |